What’s Next for Specialty Medication Benefit Design and Reimbursement

DEC. 10-11, 2019 | HILTON MARK CENTER | ALEXANDRIA, VA
PLEASE BE ADVISED

Photographs and/or video taken during this AMCP Partnership Forum may be used in AMCP’s newsletters, website, promotions, education, and editorial content, or advertising and/or other unspecified AMCP-related materials; such images may be altered to suit various applications.

By appearing in this public place, you grant AMCP unrestricted rights to use and publish photographs or video in which you may be included and release any AMCP-contracted photographer or videographer and/or their legal representatives and assigns from all claims and liability relating to said photographs and/or video.
Dear Partnership Forum participant,

Thank you for joining the final AMCP Partnership Forum of 2019, *“What’s Next for Specialty Medication Benefit Design and Reimbursement.”* Over the next day-and-a-half, we'll address a root cause of today's high pharmaceutical spending: how to better manage the increasing number of expensive specialty medicines coming to market.

How do you plan for a million-dollar drug? How do you change systems to reduce administrative burdens and lower costs? How do you ensure patients will still have access to valuable innovation?

These are some of the questions we must answer as we modernize the specialty pharmacy benefit for the 21st century. The task before us is urgent, given that specialty medications account for nearly 50 percent of the total drug spend in the United States. This figure is only expected to grow.

To address the spending challenge, we will develop ideas for new benefit and reimbursement designs that allow patients to access needed specialty medications, while also allowing payers to remain good stewards of limited resources. Our recommendations will focus on ways to:

- Reduce costs for beneficiaries while maintaining or improving access to prescription drugs
- Support marketplace competition and incentives for biopharmaceutical innovation
- Minimize physicians' burden and the financial risk associated with managing drug inventories
- Remove adverse reimbursement incentives for prescribing higher priced drugs
- Consider the cost-effectiveness of treatments and services across the health care continuum
- Support mechanisms to support quality measurement or program evaluation metrics

This is a tall order, but I know the depth and breadth of expertise represented at this Partnership Forum will get the job done. Thank you again for sharing your knowledge and experience on this important topic. And as always, all findings and recommendations will be published in an upcoming issue of AMCP’s *Journal of Managed Care & Specialty Pharmacy*. Finally, I'd like to thank our sponsors who made this forum possible: Amgen, AstraZeneca, Bayer, GSK, Merck, Pfizer, PhRMA, Takeda, Xcenda.

I look forward to a very productive event.

Sincerely,

Susan A. Cantrell, RPh, CAE
AMCP CEO
WHAT'S NEXT FOR SPECIALTY MEDICATION BENEFIT DESIGN AND REIMBURSEMENT

MODERATOR

Susan Winckler, RPh, Esq.
President
Leavitt Partners Solutions

Susan Winckler, RPh, Esq. is president of Leavitt Partners Solutions and chief risk management officer for the Leavitt Partners family of businesses. A pharmacist and attorney by training, Susan advises corporate executives on policy and business matters, such as Medicare/Medicaid, FDA practices and alternative payment models. Prior to joining Leavitt Partners, Susan served as CEO of the Food & Drug Law Institute from 2009–2014, where she provided attorneys, regulators, industry leaders, and consumers with journals, meetings, and a neutral forum for addressing domestic and global food and drug law issues. As FDA chief of staff from 2007–2009, Susan served as the interface between the commissioner and the FDA centers, as well as the agency and HHS and the White House. In a separate management role, she led FDA’s Offices of Legislation, External Relations, Public Affairs and Executive Secretariat. As vice president of policy and communications and staff counsel for the American Pharmacists Association, Susan served as the association’s lead spokesperson and senior liaison to Congress, the executive branch, state associations, and allied groups. Born and raised in the Midwest, Susan earned a Bachelor of Science from the University of Iowa College of Pharmacy and her Juris Doctor magna cum laude from Georgetown University Law Center.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 – 2:30pm</td>
<td>Welcome and Introductions</td>
</tr>
<tr>
<td>2:30 – 3:15pm</td>
<td>Presentation: Specialty Drugs Continue to Drive the Pharmacy and PBM Industries</td>
</tr>
<tr>
<td>3:15 – 4:15pm</td>
<td>Panel 1: Understanding an Evolving Marketplace Challenges with the Current Systems</td>
</tr>
<tr>
<td>4:15 – 4:30pm</td>
<td>Break</td>
</tr>
<tr>
<td>4:30 – 5:45pm</td>
<td>Breakout Session 1: Strengths and Weaknesses of Specialty Medication Benefit Design and Reimbursement</td>
</tr>
<tr>
<td>5:45pm</td>
<td>Reception</td>
</tr>
</tbody>
</table>
## Agenda

**Wednesday, Dec. 11**

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 – 8am</td>
<td>Breakfast</td>
</tr>
<tr>
<td>8 – 8:15am</td>
<td>Welcome and Day 1 Debrief</td>
</tr>
<tr>
<td>8:15 – 9:15am</td>
<td>Panel 2: Opportunities to Modernize Specialty Medication Payment Systems</td>
</tr>
<tr>
<td></td>
<td>Break</td>
</tr>
<tr>
<td>9:15 – 9:30am</td>
<td>Breakout Session 2: Opportunities: Advancing Payment Models to Lower Drug Costs for Patients</td>
</tr>
<tr>
<td>9:30 – 11am</td>
<td>Networking Lunch</td>
</tr>
<tr>
<td>11 – 11:45am</td>
<td>Panel 3: Tackling Threats to Modernize Payment of Specialty Medications</td>
</tr>
<tr>
<td>11:45am – 12:45pm</td>
<td>Breakout Session 3: Tackling Threats to Modernize Payment of Specialty Medications with PESTLE Analysis</td>
</tr>
<tr>
<td>12:45 – 1pm</td>
<td>Break</td>
</tr>
<tr>
<td>1 – 2:30pm</td>
<td>Full Group Discussion: Acting on Strengths and Seizing Opportunities for AMCP and Stakeholders</td>
</tr>
<tr>
<td>2:30 – 3pm</td>
<td>Forum Summary and Conclusions</td>
</tr>
</tbody>
</table>
WHAT'S NEXT FOR SPECIALTY MEDICATION BENEFIT DESIGN AND REIMBURSEMENT

PARTICIPANTS

**Pooja Babbrah, MBA**  
Senior Consultant  
Point-of-Care Partners

Pooja Babbrah, MBA is Point-of-Care Partners’ practice lead for PBM services and is a co-chair of the National Council for Prescription Drug (NCPD) Programs’ Specialty Pharmacy Work Group, formed in 2018 in response to stakeholder demand to automate and standardize specialty pharmacy transactions. A senior health care information technology (IT) consultant, Pooja specializes in product management, strategic planning, and go-to-market strategies and execution. With more than 20 years of experience in various health care services and health care IT companies, she brings a unique expertise to the clients as she understands the perspectives of all stakeholders including PBMs, health plans, patients, physicians, ePrescribing, electronic medical record vendors, and hospitals/health systems.

**Lisa Cashman, PharmD**  
Director, Clinical Account Services  
MedImpact Healthcare Systems

Lisa Cashman, PharmD has 20 plus years of health care experience, including pharmacy benefit management and understanding client goals across Medicare Part D, commercial insurance, Medicaid, and health insurance exchange. Her clinical program management team consults clients on formulary, utilization management, clinical intervention programs, and drug spend and trend management. Previously, she was responsible for MedImpact formulary management strategy and execution ensuring clinical appropriateness, optimal financial performance, reporting, regulatory compliance, specialty drug management, and drug information and data. She received a Bachelor of Arts from the University of California (UC), San Diego, and a Doctor of Pharmacy from UC, San Francisco. She completed a general residency at the VA Medical Center Department of Medicine in Palo Alto, Calif. She’s an AMCP member and serves on the AMCP Executive Format Committee.

**Richard Demers, RPh, MS**  
Chief Administrative Officer, Ambulatory Pharmacy Services  
Penn Medicine

Richard Demers, RPh, MS, is the chief pharmacy executive for all Penn Medicine ambulatory pharmacy services, including infusion, retail, and specialty pharmacy services for six hospitals, 11 retail pharmacies, and three infusion satellites. He received his Bachelor of Science at Northeastern University, Master of Science in hospital pharmacy from The Ohio State University (OSU), and residency in hospital pharmacy from OSU Hospitals (OSUH). Rick was assistant director of pharmacy at OSUH for four years. He then joined Exeter Hospital as director of pharmacy in Exeter, N.H. The Department of Pharmacy received a “Best Practices Award” from the American Society of Health-System Pharmacists (ASHP) in 2013. Rick is an ASHP fellow and president of the Pennsylvania Pharmacists Association. Previously, he was the president of the Pennsylvania Society of Health System Pharmacists.
WHAT'S NEXT FOR SPECIALTY MEDICATION BENEFIT DESIGN AND REIMBURSEMENT

PARTICIPANTS

Sara Deno, PharmD
Managed Care Pharmacist

Sara Deno brings 15 years of specialty pharmacy and managed care experience with a focus on health plans and their customers. Most recently, Dr. Deno held the position of consultant specialty pharmacist for United Healthcare Pharmacy. In this role, she developed and implemented specialty pharmacy management programs across both the pharmacy and medical benefits. In addition, she worked with plan sponsors and consultants to discuss specialty pharmacy management under the medical benefit. Prior to this, she held several positions with pharmacy benefit management and specialty pharmacy companies interfacing with health plans such as Kaiser Permanente, Aetna, and United Healthcare. She earned her Doctor of Pharmacy from the University of Minnesota, Twin Cities campus.

Julie DiTucci-Reiter, PharmD
Clinical Policy and Programs
Steward Health Choice

Julie DiTucci-Reiter, PharmD joined Steward Health Care in April 2017. Her responsibilities include medical drug policy development, clinical and formulary management strategies, PBM oversight, and other clinical programs with emphasis on high-cost specialty drugs. Dr. DiTucci-Reiter has more than 20 years of experience in managed care clinical roles with participation on several P&T committees involving Medicaid, Medicare, and commercial lines of business. Prior to joining Steward Health Care, Dr. DiTucci-Reiter held various positions at Molina Healthcare Inc. and Presbyterian Health Plan. Dr. DiTucci-Reiter received her Bachelor of Science in pharmacy and Doctor of Pharmacy from the University of New Mexico.

Claire Dybala, PharmD
Senior Director, Account Medical Lead Team
Takeda

Claire Dybala, PharmD is the senior director for the account medical lead (AML) team at Takeda Pharmaceuticals USA. Her work focuses on leading the AML team to build medical partnerships with payers. Dr. Dybala has been with Takeda for more than 14 years where she has held multiple strategic and operational leadership roles within medical affairs. In addition to Takeda, Dr. Dybala has held medical affair positions at Johnson & Johnson and Abbott. Dr. Dybala earned a Bachelor of Science from the University of Illinois at Urbana-Champaign and a Doctorate in Pharmacy from the University of Illinois at Chicago.
WHAT'S NEXT FOR SPECIALTY MEDICATION BENEFIT DESIGN AND REIMBURSEMENT

PARTICIPANTS

Stephen George, PharmD, MS
Milliman

Stephen George, PharmD, MS is a pharmacist with 30 years of experience. He serves as a senior consultant assisting clients in various areas including health care plan pharmacy operations, management of physician-administered and specialty drugs, integration of pharmacy and medical outcomes analysis, and developing ROI evaluations on medical interventions. Dr. George has experience in a variety of patient care and management settings, including managed care, hospital, care management, and clinical trials. He has experience with health policy analysis, pharmacoeconomics and outcomes research, auditing PBM/specialty pharmacy contracts, integrating medical/pharmacy spend, analyzing medical pharmacy benefits, and developing “best in class” clinical applications.

Estay Greene, PharmD, MBA
Vice President, Pharmacy Services
Blue Cross Blue Shield of North Carolina

Estay Greene, PharmD, MBA is vice president of pharmacy programs for Blue Cross Blue Shield of North Carolina (Blue Cross NC), managing prescription drug program and benefits including planning, coordinating, and directing the development and implementation of prescription drug benefits and pharmacy management programs, initiatives, and functions. Previously, he was director of pharmacy benefits for the Cleveland Clinic/Cleveland Health Network. He was responsible for the operation, coordination, and implementation of the prescription drug program, was well as designing disease management strategies to improve pharmaceutical care outcomes and implementing Medicare Part D strategies. Dr. Greene was clinical pharmacy specialist for Kaiser Permanente of Ohio and pharmacy manager/clinical pharmacist for Rite Aid Pharmacies. He received his Doctor of Pharmacy from Duquesne University and Master of Business Administration from the University of Phoenix.

Dorothy Hoffman
Healthcare Innovation Center – Access Innovation Lead
Pfizer

Dorothy Hoffman is access innovation lead in Pfizer’s Healthcare Innovation Center, where she implements new access, affordability, and patient engagement models with government and commercial payers, PBMs, hospitals, health tech companies, and patient groups. She addresses social determinants of health and creates new financing and payment models for gene therapies. Dorothy also leads the Healthcare Innovation Center’s business development strategy. Prior to Pfizer, Dorothy was vice president of prescription drug policy at UnitedHealth Group, partnering with OptumRx and UnitedHealthcare leadership to implement their pharmacy transformation and growth initiative, including direct-to-consumer pharmacy discounts, real-time benefit tools at the point-of-prescribing, and enhanced specialty pharmacy capabilities. Previously at Lilly, Dorothy led development for innovative payer-PBM partnerships focused on value-based arrangements, pre-approval communications, and patient affordability. Dorothy has a Master in Public Policy.
WHAT'S NEXT FOR SPECIALTY MEDICATION BENEFIT DESIGN AND REIMBURSEMENT

PARTICIPANTS

Daniel Kent, PharmD, CDE
Specialty Clinical Pharmacy Quality Coordinator
Kaiser Permanente of Washington

Daniel Kent, PharmD, CDE has been a specialty clinical pharmacy quality coordinator with Kaiser Permanente in the state of Washington for 40 years. His role is to implement new and innovative ways to deliver health care drug therapies using expensive and complex drugs. Implementation includes program designs for an integrated health plan and delivery system based on affordability, quality, safety, and improved patient care in the areas of diabetes, infectious diseases, vaccines, and hepatitis B/C. Dr. Kent’s responsibilities include resource stewardship with the primary endpoint on care improvements, tracking/integrating new drugs, clinical training for patients and staff, and building/managing data systems in various areas.

George Kitchens, RPh
President
Artia Solutions, LLC

George founded Artia Solutions LLC in 2005 and ensures it provides top-notch consultation services to clients who need assistance operating within the Medicaid pharmaceutical environment. Previously, George was vice president of business development for Provider Synergies, which manages rebate programs for Medicaid. He developed the multi-state pooling initiative, TOP$. George was also the Florida Medicaid’s Pharmacy Services bureau chief for three years, implementing the nation’s first PDL in 2001. He planned, directed, organized, and coordinated policies and procedures for the Medicaid prescribed drug program as well as researched and analyzed proposed state and federal legislation, Medicaid prescribed drug budget, and cost containment initiatives. Before joining Florida Medicaid, George held numerous positions for the Eckerd Corporation.

Grant Knowles, PharmD, CSP
VP, Business Development & Industry Relations
Ardon Health

Grant Knowles, PharmD, CSP is the vice president of business development and industry relations at Ardon Health. He played an integral role in the development of Ardon Health’s specialty pharmacy as the vice president of operations. He earned his Doctor of Pharmacy at Drake University and is residency-trained in managed care pharmacy. He’s an expert in specialty pharmacy management from a payer, provider, and contracting perspective. His career started at American Health Care in population health management, where he directed operations, client presentations, and maintained continuing education programs. Prior, he led Moda Health’s formulary management initiatives for Medicaid, Medicare, and commercial clients. He’s co-chair of the National Association of Specialty Pharmacy Clinical Outcomes Committee and is a founding member of AMCP’s Northwest affiliate, where he serves as the current president.
WHAT’S NEXT FOR SPECIALTY MEDICATION BENEFIT DESIGN AND REIMBURSEMENT

PARTICIPANTS

Kollet Koulianos, MBA
Senior Director Payer Relations
National Hemophilia Foundation

Kollet Koulianos, MBA serves as the senior director of payer relations for the National Hemophilia Foundation (NHF). Her responsibilities include project leadership, analysis, and development of NHF’s health care payer education strategies, policies, and programs, including the Comprehensive Care Sustainability Collaborative. Previously, Kollet served as the executive director of the Bleeding & Clotting Disorders Institute, a federally recognized Hemophilia Treatment Center of Excellence. She also served on the executive board of directors for the Hemophilia Alliance and chaired their national payer subcommittee, as well as participated on the Illinois Hemophilia Advisory board.

Lauren Liggett
Director, Strategic Market Access
Xcenda

Lauren is currently director of strategic market access at Xcenda. Lauren spent her career on the manufacturer side, working for both small and large pharmaceutical companies in U.S. and global roles. Most recently she led the market access strategy for an oncology portfolio, ensuring customer understanding of the clinical, economic, and humanistic value of the treatments. She’s led commercialization strategy for new assets and new indications of on-market assets spanning the oral and IV space. Lauren earned a Master of Arts in economics from American University, and Bachelor of Arts in economics and Hispanic studies from Boston College.

Greg Low, RPh, PhD
Director, Massachusetts General Physicians Organization’s Pharmacy Quality and Utilization Program
Massachusetts General Hospital

Greg Low, RPh, PhD is the director for the Massachusetts General Physicians Organization’s (MGPO) Pharmacy Quality and Utilization Program at Massachusetts General Hospital, Boston. He’s a member of the Massachusetts Drug Utilization Review Board and the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council. At the MGPO, Dr. Low works with clinical leadership to develop, implement, and evaluate ambulatory pharmacy programs. His efforts include addressing pharmacy’s contribution to total medical expense, physician variation reporting, accountable care organization reporting, and academic detailing. Dr Low received his Bachelor of Science in pharmacy and Doctor of Philosophy in pharmacoepidemiology and pharmacoconomics from the University of Rhode Island.
George Mayzell, MD, MBA
Principal
Empowered Healthcare

George Mayzell, MD, MBA is the founder and president of Empowered HealthCare, specializing in population health, care management redesign, clinical variation, clinical integration, and physician leadership. Prior roles include chief clinical officer of Vizient Southeast; senior vice president/chief medical officer and chief clinical integration officer for AMITA Health; positions at Adventist Midwest Health; CEO of Health Choice; senior vice president of Methodist Le Bonheur Healthcare; senior medical director of managed care for University of Florida and Shands Hospital; and regional medical director for care and quality and corporate managing medical director for pharmacy and care at Blue Cross Blue Shield of Florida. Dr. Mayzell is a board certified internist and geriatrician. He received his Doctor of Medicine from Rutgers University and Master of Business Administration from Jacksonville University.

Natalie Morris, JD, MPP
Head of U.S. Policy
AstraZeneca

Natalie Morris is the head of U.S. policy for AstraZeneca, where she leads a team that develops and executes strategies to shape the federal policy environment to advance business-aligned goals and objectives. Prior to joining AstraZeneca, Natalie was a member of Avalere Health’s reimbursement and product commercialization group. Prior to her time at Avalere, Natalie was an associate in the health law practice of the law firm Hogan Lovells, where she focused on Medicare and Medicaid programs. Natalie holds a Juris Doctor and a Bachelor of Arts from the University of Virginia as well as a Master of Public Policy from George Mason University.

Gary Owens, MD
President
Gary Owens Associates

Gary Owens, MD has 35 years of experience in health care management. He was actively involved in the managed care movement of the 1990s, which evolved to the current era of health care coverage and payment reform. Dr. Owens provides strategic and tactical consulting services to a wide range of clients including pharmaceutical manufacturers, device manufacturers, and other developers of new technology. He has presented extensively on managed care, including at conferences of the AMCP, the National Association of Managed Care Physicians, and the Association for Value-based Cancer Care. Dr. Owens is the past chair of the Arthritis Foundation of Eastern Pennsylvania and he was a former member of the Foundation’s Northeast regional board of directors. Dr. Owens was the first physician to serve (2014–2018) as an AMCP board member.
Vincent Pacileo is the director of federal affairs for the Arthritis Foundation and leads the federal policy, legislative, and regulatory affairs programs. Vincent joined the Foundation from the American Psychiatric Association (APA), the oldest medical association in the country, where he managed a portfolio of policy issues including mental health reform, public health programs, substance use, and pharmaceuticals/medical devices. Prior to APA, he worked at West Health on policy and analytic projects to advance the organization’s mission to lower the cost of health care. Vincent previously provided policy and research support to the government affairs teams at Vertex Pharmaceuticals. He earned his Master of Public Policy from The George Washington University and bachelor’s degree from the University of Connecticut.

Ashish Patel, PharmD is the director of quality, compliance and business development at Inland Empire Health Plan (IEHP) and has more than 10 years of managed care and community pharmacy experience. He develops new pharmacy clinical programs and partnerships, driving operational and clinical quality and strengthening the delivery of pharmacy care. He received his Doctor of Pharmacy at the University of California, San Francisco and his Bachelor of Arts at the University of California, Berkeley.

As vice president of pharmacy and vendor relationship management at Community Health Plan of Washington, Yusuf Rashid, RPh, oversees prescription and medical benefit pharmacy programs as well as ancillary vendor services supporting the medical management division. His responsibilities include prescription drug benefit strategy, formulary design, PBM relations, and pharmacy clinical programs. Yusuf is responsible for integrating strategic medical vendor services to optimize quality of care at sustainable costs. Other vendor experience includes utilization management independent review organizations, specialized case management, health risk assessments, health home care coordination services, nurse advice line, data integration platforms, medication therapy management, and care management software systems. He serves as an appointed member of the Washington Health Care Authority Emerging Therapies Workgroup.
Carly Rodriguez, PharmD, FAMCP
Pharmacy Director, Clinical Innovation
Moda Health

Carly Rodriguez, PharmD, FAMCP is pharmacy director, clinical innovation for Moda Health. In this role, she provides strategic leadership for clinical initiatives, operations, innovation, and the integration and management of medications across pharmacy and medical benefits. Her areas of expertise include formulary management, cost-savings and utilization management strategies, specialty drug management, benefit design, and medical pharmacy. She’s presented to a variety of audiences on important topics in managed care, such as specialty pharmacy, data integration, and trend management. Carly received her Doctor of Pharmacy from the University of Washington, along with a certificate in biomedical and regulatory affairs. She was recognized as a fellow of the Academy of Managed Care Pharmacy in 2019 for exceptional contribution, commitment, and sustained excellence in managed care pharmacy.

Brett Sahli, PharmD
Senior Director Specialty Pharmacy
Programs and Strategy
Prime Therapeutics

Brett Sahli, PharmD received his Doctor of Pharmacy from the University of Minnesota. He’s spent his career in various areas of drug benefit management and managed care practice. He’s spent much of his time at OptumRx and UnitedHealth Care entities developing specialty pharmacy assessment and care programs for members, as well as conducting formulary management and manufacturer contracting. He spent one year practicing employer group pharmacy benefit consulting with Pharmaceutical Strategies Group prior to his current position where he is senior director of specialty pharmacy programs at Prime Therapeutics, focusing on high cost and medical benefit drug management strategies.

Mitchel Seleznick, MD, MPH, MBA, FACP
Medical Director
CarePlus Health Plans Pharmacy

Mitchel Seleznick, MD, MPH, MBA, FACP, is a medical director at CarePlus Health Plans. He’s engaged in population health management, pharmacy review, and patient safety. He received his Bachelor of Science from Washington and Lee University; Doctor of Medicine from the State University of New York, Downstate; Master of Public Health at the University of South Florida; and Master in Business Administration at the University of Massachusetts. He completed residency at Mount Sinai Hospital in New York and fellowship at Stanford University. Dr. Seleznick is board certified in internal medicine, rheumatology, and allergy and immunology. He’s a collaborative professor of internal medicine at the University of South Florida. Dr. Seleznick has published and presented in a variety of journals and conferences.
WHAT'S NEXT FOR SPECIALTY MEDICATION BENEFIT DESIGN AND REIMBURSEMENT

PARTICIPANTS

Lyssa Siffring
Director, Specialty Brand Payer and Access Marketing
GSK

Lyssa Siffring has more than 10 years of experience in the pharmaceutical industry holding commercial roles at both GSK and AbbVie, with the last six years focused in specialty products. Prior to entering the industry, she held field clinical roles in medical devices and spent over four years in management consulting. Lyssa graduated with a Bachelor of Science in business administration from the University of North Carolina at Chapel Hill and a Master in Business Administration from the University of Michigan.

Irina Smith, PharmD, CSP
Specialty Pharmacist – Policies
CareSource

Irina Smith, PharmD, CSP currently serves as the specialty pharmacist-policies at CareSource Management Group Co., and has expertise in specialty drug policies and initiatives, formulary and utilization management, biosimilars and gene therapies, P&T committee, pipeline, medical drug benefits, and pharmacy operations. Dr. Smith created and implemented more than 150 specialty drug policies for each Medicaid line of business at CareSource in the past three years. She’s passionate about specialty drug education and hopes to inspire others to pursue specialty medications. Dr. Smith’s an active member of AMCP since 2012 and has more than seven years of managed care experience.

Jason Spangler, MD, MPH, FACPM
Executive Director
Amgen Inc.

Jason Spangler, MD, MPH, FACPM is executive director of value, quality, and medical policy at Amgen, leading policy issues related to health economics and value, health care quality, and engagement with U.S. federal payer agencies. Previously, Dr. Spangler was chief medical officer at Partnership for Prevention and public health and health policy consultant at Pfizer. His additional roles include American College of Preventive Medicine fellow, board regent, and alternate delegate to the American Medical Association; Pharmacy Quality Alliance board director; and University of Michigan Center for Value-based Insurance Design’s board advisor. He received his Doctor of Medicine at Pennsylvania State University. He completed his internal medicine residency at the University of Pittsburgh and preventive medicine residency at the Johns Hopkins University, where he was chief resident. He’s board certified in general preventive medicine/public health.
WHAT’S NEXT FOR SPECIALTY MEDICATION BENEFIT DESIGN AND REIMBURSEMENT

PARTICIPANTS

Debbie Stern, RPh
President
Rxparts Consulting

Debbie Stern, RPh, is president of Rxparts, a managed care consulting firm. She has more than 20 years of experience consulting in pharmaceutical and specialty pharmacy marketing, clinical program development, market assessment, strategy development, and strategy execution for pharma, health plans, PBMs, technology companies, and specialty pharmacies. Debbie was senior vice president for oncology and specialty drug management at eviCore healthcare, a senior level director at two PBMs. She spent five years in the pharmaceutical industry and 10 years in retail pharmacy. Debbie initiated the EMD Serono Specialty Digest™ and wrote and edited editions one through 11. She has a Bachelor of Science in pharmacy from the University of Cincinnati and is active in AMCP, where she served on the board of directors and chaired the Program Planning Committee.

Daniel Tomaszewski, PharmD, PhD
Assistant Professor, Managed Care Consultant
Chapman University School of Pharmacy

Daniel Tomaszewski, PharmD, PhD, is an assistant professor in pharmacy administration at Chapman University School of Pharmacy. Dr. Tomaszewski has had a variety of teaching, practice, and research experiences, including providing direct patient care and managed care. Dr. Tomaszewski’s current research efforts are focused on health economic and outcomes research, including assessment of the impact of opioid use in pediatric patients, the effects of medication non-adherence, and the impact of biologics and biosimilars on the U.S. health care system. In addition, Dr. Tomaszewski provides managed care consulting with a variety of payers to enhance clinical programs and pharmacy service administration.

Laura Topor
President
Granada Health Inc.

Laura Topor is president of Granada Health Inc., a Minnesota-based consulting firm. Laura has more than 25 years of experience in pharmacy benefits management, payer and provider operations, regulatory compliance, process improvement, and strategic planning. She’s worked with the Minnesota Department of Health, PharmaSmart, BenMedica, PricewaterhouseCoopers, Allina, HealthPartners and Diversified Pharmaceutical Services. She’s an active member of NCPDP, AMCP, Minnesota Pharmacists Association, and the Minnesota eHealth Initiative. At NCPDP, Laura served as a member of the board of trustees, work group, and standardization co-chair, as well as on numerous committees and task groups. She currently serves as co-chair of NCPDP’s Specialty Pharmacy Work Group and was appointed to AMCP’s Specialty Pharmacy Advisory Group and it health IT Advisory Council.
Hai Tran, PharmD, BCPS
Associate Director, Drug Use Policy
Cedars Sinai Medical Center

Hai Tran, PharmD, BCPS is the associate director for the Drug Use Policy Pharmacy at Cedars-Sinai Medical Center, an 863-bed acute tertiary care, teaching institution in Los Angeles. She oversees the Antimicrobial Stewardship Program, formulary management, the hospital’s pharmacy clinical program. She’s also responsible for developing and implementing cost-saving strategies in collaboration with medical and nursing leadership.

Katie Verb
Director, Policy & Research
PhRMA

Katie Verb is a director of policy & research at PhRMA, where she helps drive the policy agenda around Medicare Part B, biosimilars, and cell and gene therapy. Previously, Katie led policy and government relations at the Hemophilia Federation of America (HFA), where for nearly five years she directed the policy agenda, served as a federal advocate, and assisted states in advocating for patients with bleeding disorders. Before HFA, Katie was a member of the government affairs team at the Toy Industry Association working on regulatory issues involving consumer product safety and international trade.

Neil Warnock, MD
Deputy Director, Medical Affairs – Market Access
Bayer

Neil Warnock, MD has more than 19 years of field-based experience in a variety of therapeutic areas, serving as a scientific and educational resource in managed care, health systems and health economics and outcomes research, supporting national and regional market access teams in a variety of management and individual contributor roles. His work experience includes positions held at large pharmaceutical companies and smaller biotechnology organizations where he has specialized in resource development to fulfill key performance and evidence gaps from the payer perspective, using a variety of scientific communication platforms and data analytics to convey value propositions.
Thank You
To our distinguished participants and guests.

About AMCP
AMCP is the professional association leading the way to help patients get the medications they need at a cost they can afford. AMCP’s diverse membership of pharmacists, physicians, nurses, and professionals in life sciences and biopharmaceutical companies leverage their specialized expertise in clinical evidence and economics to optimize medication benefit design and population health management, and help patients access cost-effective and safe medications and other therapies. AMCP members improve the lives of nearly 300 million Americans served by private and public health plans, pharmacy benefit management firms, and emerging care models.

AMCP Mission
To improve patient health by ensuring access to high-quality, cost-effective medications and other therapies.

AMCP STAFF AND Consultants

Susan A. Cantrell, RPh, CAE
Chief Executive Officer

Phil Bongiorno
Vice President, Policy & Government Relations

Rebecca Corey
Manager, Projects and Operations BBCIC

Judy Crespi-Lofton, MS
Medical Writer and Consultant JCL Communications LLC

Abigail Fredenburg, MA
Director, Integrated Marketing & Communications

Julian Greer, CMP
Senior Manager, Meetings & Forums

Brittany Henry, PharmD, MBA
Assistant Director, Educational Program

Cate Lockhart, PharmD, PhD
Executive Director BBCIC

Matt Lowe
Vice President, Business Strategies

Zain Madhani
Program Manager, Policy & Government Relations

Noreen Matthews, BSN, MBA
Senior Consultant, Business Strategies

Kristine Paschalis, MSW
Director, Education

Cynthia Reilly, MS, BS Pharm
Chief Operating Officer

Terry Richardson, PharmD, BCACP
Senior Pharmacist Consultant

Ruby Singh, PharmD, BCPS
Vice President, Education & Training
Findings and recommendations from this event will be published in an upcoming issue of AMCP’s *Journal of Managed Care & Specialty Pharmacy*, and will be widely disseminated to decision makers around the country.